Bayer settles some NSF cases
Radiology ‘Wikipedia’ settles in on web
Bayer settles some NSF cases
Bayer has tentatively settled between 30 and 40 lawsuits brought by patients who developed nephrogenic systemic fibrosis after the administration of Magnevist, its MR contrast agent. Only Bayer has so far reached any such settlements, according to Peter Burg, an attorney with Burg Simpson Eldredge Hersh & Jardine in Englewood, CO, who told DI SCAN that not all of the tentative deals involve his clients. Bayer and several other makers of gadolinium-based contrast agents are facing hundreds of lawsuits alleging a link between the administration of the agents and NSF, a potentially fatal disease characterized by uncontrolled growth of connective tissue in the skin and internal organs. In September 2007, the FDA asked manufacturers of these agents -- Bayer (Magnevist), GE Healthcare (Omniscan), Mallinckrodt/Tyco Healthcare (OptiMark), and Bracco Diagnostics (ProHance and MultiHance) -- to add a black-box warning about NSF. The agency at the time also warned patients with impaired kidney function to avoid gadolinium-containing agents.
Radiology ‘Wikipedia' settles in on web
A specialist version of Wikipedia aimed at the radiology community is on the web. Radiopaedia.org is a free online radiology resource built and maintained by users, who find and correct errors. Currently in beta form, Radiopaedia.org is being framed as the means to support discussion of difficult or controversial topics. Images and other materials can be submitted and downloaded for use by others under Creative Commons 3.0 license.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
